---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-024363"
form_type: "8-K"
ticker: "OGEN"
cik: "0001174940"
company_name: "ORAGENICS INC"
filed_at: "2026-05-19T12:38:18+00:00"
generated_at: "2026-05-19T12:41:07.516388+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Oragenics dosed first patient in Phase IIa concussion trial; signs LOI for CNS device

## Summary
- Phase IIa trial of ONP-002 in Australia active; first patient dosed at Mackay Base Hospital March 2026.
- Signed LOI to license a complementary CNS medical device; expands addressable indication set beyond ONP-002.
- Cash balance $6.1M as of Q1 2026; R&D expenses $0.6M (up 89% YoY); G&A $1.6M (down 4% YoY).
- Targets Type C meeting with FDA in Q2 2026, IND submission by end of 2026, Phase IIa data readout in 2026.

## SEC filing metadata
- accession: 0001493152-26-024363
- form_type: 8-K
- ticker: OGEN
- cik: 0001174940
- company_name: ORAGENICS INC
- filed_at: 2026-05-19T12:38:18+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1174940/000149315226024363/0001493152-26-024363-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1174940/000149315226024363/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-024363
- JSON: https://secwatch.observer/filing/0001493152-26-024363.json
- Plain text: https://secwatch.observer/filing/0001493152-26-024363.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.